This study is completed in Argentina, in Bulgaria, in Croatia, .... It is testing pimavanserin for schizophrenia.
SchizophreniaDrugFrom 18 Years to 55 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether Pimavanserin as Adjunctive Treatment may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive Pimavanserin as Adjunctive Treatment, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Argentina, in Bulgaria, and in Croatia.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: August 5, 2020
Recruitment status
Completed
Enrollment listed in the registry
454
Sponsor
ACADIA Pharmaceuticals Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Argentina, Bulgaria, Croatia, ...
Age range
From 18 Years to 55 Years
Official registry ID
NCT04531982
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
573-"SBIH of Moscow ""Psychiatric Clinical Hospital # 4 n.a. P.B. Gannushkin"" Short name: PCH N4 n.a. P.B.Gannushkin"
Moscow
Site status: Not listed — confirm with the team
581-SBIH of Moscow "Psych Clinical Hospital #1 N.A. Alekseev"
Moscow
Site status: Not listed — confirm with the team
415-Saint-Petersburg state healthcare institution "Saint Nicolas wonderworker psychiatric hospital"
Saint Petersburg
Site status: Not listed — confirm with the team
571-St. Petersburg SHI "Psychoneurological Dispensary #10"
Saint Petersburg
Site status: Not listed — confirm with the team
451-V. M. Bekhterev National Research Medical Center For Psychiatry and Neurology
Saint Petersburg
Site status: Not listed — confirm with the team
453-"Saint-Petersburg Scientific Research Psychoneurological Institute n.a. V.M. Bekhterev"
Saint Petersburg
Site status: Not listed — confirm with the team
465-"Saint-Petersburg Scientific Research Psychoneurological Institute n.a. V.M. Bekhterev
Saint Petersburg
Site status: Not listed — confirm with the team
495-"FSBI "National medical scientific center of psychiatry and neurology n.a. V.M. Bekhterev" MoH Short name: NMSC of Psy&Neuro n.a. Bekhterev, 12 dep."
Saint Petersburg
Site status: Not listed — confirm with the team
464-Saint Petersburg State Budget Healthcare Institution "City Psychiatric Hospital No. 6 (Inpatient Department with Treatment Center)
431-Hospital Psiquiátrico Provincial Doctor Villacian
Valladolid
Site status: Not listed — confirm with the team
529-Hospital Provincial de Zamora
Zamora
Site status: Not listed — confirm with the team
Ukraine · 9 sites
508-CI Cherkasy Regional Psychiatric Hospital of ChRC
Smila, Cherkasy Oblast
Site status: Not listed — confirm with the team
564-Regional Clinical Psychiatric Hospital
Kropyvnytskyi, Kirovohrad Oblast
Site status: Not listed — confirm with the team
460-Kyiv City Psychoneurological Hospital #3 General Psychiatry Department No. 2
Kyiv, Vasylkiv District Kyiv Region
Site status: Not listed — confirm with the team
434-State Institution "Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine", Department of Urgent Psychiatry and Narcology
Kharkiv
Site status: Not listed — confirm with the team
567-"CIH Kharkiv Regional Clinical Psychiatric Hospital #3 Psychiatric Department of Primary Psychotic Episod Short Site name: CIH KRCPH #3 PD of PPE "
Kharkiv
Site status: Not listed — confirm with the team
582-SI Institute of Neurology,Psychiatry&Narcology of NAMSU
Kharkiv
Site status: Not listed — confirm with the team
435-Kyiv Regional Medical Incorporation "Psychiatry". Center of Novel Treatment and Rehabilitation of Psychotic disorders, build 5, Department #30
Kyiv
Site status: Not listed — confirm with the team
565-"Kyiv CH on Railway Transport #2 of Branch Center of Healthcare Public Company Ukr Railway Short site name: Kyiv Railway Clinical Hospital № 2"
Kyiv
Site status: Not listed — confirm with the team
509-CI Odesa Regional Medical Centre of Mental Health
Odesa
Site status: Not listed — confirm with the team
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT04531982. We help you review the study, but cannot decide medical eligibility.
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Pimavanserin, Placebo. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 55 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by ACADIA Pharmaceuticals Inc., which appears to be another type of organization. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
